Merck KGaA registers Elowen-LTE Phase 3 lupus study and mirdametinib drug interaction trialWeekly roundup, 2 itemsMerck KGaAmirdametinib
JAVELIN Bladder Medley posts results; avelumab combos tested as maintenance therapyTrial updateavelumabM6223
Sign inSign in